{
  "docId": "019de075-0f3e-7563-9ac8-6248b1eac169",
  "docSlug": "df5bd8b83b2912100a1eb82b66046bd0",
  "documentTitle": "Theravance Biopharma | Results Presentation Deck | 41 slides",
  "authorId": "theravance-biopharma",
  "authorName": "Theravance Biopharma",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-05-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 36,
  "pageCount": 41,
  "prevPage": 35,
  "nextPage": 37,
  "slideType": "kpi_overview",
  "function": "analyze_data",
  "density": "overcrowded",
  "nDataPoints": 24,
  "notes": "The table displays projected royalties and milestones for 2023-2026, while the right side details royalty return dates for 2029 and 2031.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-0f3e-7563-9ac8-6248b1eac169/36",
  "deckHref": "/decks/019de075-0f3e-7563-9ac8-6248b1eac169",
  "deckJsonHref": "/decks/019de075-0f3e-7563-9ac8-6248b1eac169.json",
  "deckAnchorHref": "/decks/019de075-0f3e-7563-9ac8-6248b1eac169#slide-36",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.25,
        "x": 0.64,
        "y": 0.2
      },
      "kind": "callout",
      "text": "Long-Term Value",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e39ce5ed-fee8-4736-99e0-a523f9b6f142",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.25,
        "x": 0.15,
        "y": 0.2
      },
      "kind": "callout",
      "text": "Mid-Term Value",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f348ad95-5116-4147-8f16-3024fc2989bb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.85,
        "x": 0.14,
        "y": 0.9
      },
      "kind": "disclaimer",
      "text": "1. If both milestones are achieved in a given year, Theravance Biopharma will only earn the higher milestone. 2. Based on 100% of TRELEGY ELLIPTA royalties. 3. 85% of TRELEGY ELLIPTA royalties return to Theravance Biopharma beginning July 1, 2029...",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4181041c-284d-440c-bdfd-6c5f0d4b1c4b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.35,
        "x": 0.6,
        "y": 0.42
      },
      "kind": "list",
      "text": "Ex-US royalties return Jul. 1, 2029; US royalties return after Jan. 1, 2031; Paid directly from Royalty Pharma",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "774ffd6a-a56b-4ef8-af99-1aadd27c795f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.4,
        "x": 0.04,
        "y": 0.8
      },
      "kind": "metric",
      "text": "Q1'23 Net Sales of $567M | FY 2022 Net Sales of $2.1B",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b2f13426-85f7-4246-88bf-d0f2ff833d39",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.4,
        "x": 0.31,
        "y": 0.85
      },
      "kind": "source-note",
      "text": "GSK remains exclusively responsible for commercialization of TRELEGY ELLIPTA",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "23a59e12-49f8-41be-9443-1fcfaac57ed7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.8,
        "x": 0.04,
        "y": 0.13
      },
      "kind": "subtitle",
      "text": "GSK's TRELEGY ELLIPTA (FF/UMEC/VI): First and only once-daily single inhaler triple therapy",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "27836065-ff19-4b3c-8f55-908b5f4a01df",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.4,
        "x": 0.09,
        "y": 0.39
      },
      "kind": "table",
      "text": "Year, Royalties, Global Net Sales Equivalent, Milestone table",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "080cb00b-9179-4458-8c6e-a8568724136e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.5,
        "x": 0.04,
        "y": 0.05
      },
      "kind": "title",
      "text": "TRELEGY ELLIPTA Milestones and Royalties",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "df84257a-8b97-4508-af7b-d5d4280d9431",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "21c055f0-e174-469e-b4d6-982a56641378",
      "evidence": "table/data: Year, Royalties, Global Net Sales Equivalent, Milestone table",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 40,
      "from": 5,
      "beatId": "18f97180-6c3c-4b05-a378-979222504b06",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Before-After",
      "beatSlug": null,
      "evidence": "Multiple slides show progress and growth using before-after comparisons.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}